Evaluation of a Compliance Marker in Prescription Opioid Abusers With Chronic Pain
Status:
Withdrawn
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
In a small, well-characterized sample of prescription opioid abusers (POAs) with chronic pain
and on buprenorphine therapy, this study will investigate the utility and feasibility of two
novel tracer compounds, and in combination with a standard marker (riboflavin), to monitor
adherence to study drug prescription in the parent clinical trial.